Pedro Reimunde

Prof. Dr. Pedro Reimunde

Hospital Universitario Lucus Augusti
+1
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2010 in Brain Injury
Verified
Journal Article
Closed access
PDF file
PRPedro Reimunde
Pedro Reimunde
AQA. Quintana
A. Quintana
BCB. Castañón
B. Castañón
NCN. Casteleiro
N. Casteleiro
ZVZ. Vilarnovo
Z. Vilarnovo
Jesús DevesaJesús Devesa
Jesús Devesa
Objective: To assess the effects of growth hormone (GH) treatment combined with cognitive rehabilitation in patients with adult growth hormone deficiency (GHD) and cognitive disorders occurring after traumatic brain injury (TBI). Participants: Nineteen adult patients with TBI: GHD was found in 11 of them. Intervention: Patients were treated with GH (GHD; sc; 1 mg/day) or vehicle (controls; sc; 1 mg/day); daily cognitive rehabilitation therapy was performed in both groups for 3 months. Main outcome measures: The GHRH–arginine test established GHD. The neuropsychological test WAIS was performed before commencing the treatment and 3 months after commencing it. Results: Controls achieved significant improvements in digits and in manipulative intelligence quotient (IQ) (p < 0.05 vs. baseline). GHD achieved significant improvements in more cognitive parameters: understanding, digits, numbers and incomplete figures (p < 0.05 vs. baseline) and similarities, vocabulary, verbal IQ, manipulative IQ and total IQ (p < 0.01). GHD reached significantly greater improvements than controls in similarities (p < 0.01) and in vocabulary, verbal IQ and total IQ (p < 0.05). Conclusion: GH administration significantly improved cognitive rehabilitation in GHD patients. Since at the end of treatment period plasma IGF-I levels were similar in both groups it is likely that exogenous GH administration is responsible for the significant differences found.

1 February 2013 in Hormones and Behavior
Verified
Journal Article
Closed access
Jesús DevesaJesús Devesa
Jesús Devesa
PRPedro Reimunde
Pedro Reimunde
PDPablo Devesa
Pablo Devesa
MBMatías Barberá
Matías Barberá
VAVíctor M. Arce
Víctor M. Arce

14 March 2011 in Brain Injury
Verified
Journal Article
Closed access
PDF file
PDPablo Devesa
Pablo Devesa
PRPedro Reimunde
Pedro Reimunde
RGRosalía Gallego
Rosalía Gallego
Jesús DevesaJesús Devesa
Jesús Devesa
VAVíctor M. Arce
Víctor M. Arce
Primary objective: This study was designed to investigate the effect of growth hormone treatment on the proliferation of endogenous neural progenitor cells in the dentate gyrus (DG) of the brain stimulated by kainic acid (KA)-induced neurotoxicity. Research design: Neurotoxicity was induced by intraperitoneal injection of KA. GH treatment lasted 4 days, starting either immediately or after 10 days of administration of the neurotoxic insult. Methods and procedure: Proliferating cells were immunodetected after labelling by in vivo administration of 5-bromodeoxyuridine (BrdU). GH expression was detected by in situ hybridization and immunofluorescence. Main outcomes and results: KA administration stimulated the proliferation of hippocampal precursors and this effect was significantly enhanced by GH treatment. Hippocampal GH expression was also up-regulated in response to KA administration. Conclusions: The findings support the possibility that the proliferative response observed in the hippocampus of rats treated with KA and GH is a consequence of cooperation between the exogenous and the locally-produced hormone and their synergism with other mitogenic factors generated in response to the neurotoxic damage. Therefore, GH treatment could be used to cooperate with other physiological or pathological stimuli in order to promote cell proliferation.

9 July 2021 in Nanomaterials
Verified
Journal Article
Open access
PDF file
APAlba Pensado
Alba Pensado
JFJuan Fernández-Rey
Juan Fernández-Rey
PRPedro Reimunde
Pedro Reimunde
JCJosé Crecente-Campo
José Crecente-Campo
Laura SánchezLaura Sánchez
Laura Sánchez
Fernando Torres AndonFernando Torres Andon
Fernando Torres Andon
New nanoparticles and biomaterials are increasingly being used in biomedical research for drug delivery, diagnostic applications, or vaccines, and they are also present in numerous commercial products, in the environment and workplaces. Thus, the evaluation of the safety and possible therapeutic application of these nanomaterials has become of foremost importance for the proper progress of nanotechnology. Due to economical and ethical issues, in vitro and in vivo methods are encouraged for the testing of new compounds and/or nanoparticles, however in vivo models are still needed. In this scenario, zebrafish (Danio rerio) has demonstrated potential for toxicological and pharmacological screenings. Zebrafish presents an innate immune system, from early developmental stages, with conserved macrophage phenotypes and functions with respect to humans. This fact, combined with the transparency of zebrafish, the availability of models with fluorescently labelled macrophages, as well as a broad variety of disease models offers great possibilities for the testing of new nanoparticles. Thus, with a particular focus on macrophage–nanoparticle interaction in vivo, here, we review the studies using zebrafish for toxicological and biodistribution testing of nanoparticles, and also the possibilities for their preclinical evaluation in various diseases, including cancer and autoimmune, neuroinflammatory, and infectious diseases.

28 February 2006 in European Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
MOMiguel Fernández Del Olmo
Miguel Fernández Del Olmo
PRPedro Reimunde
Pedro Reimunde
OVOscar Viana
Oscar Viana
RMRafael Martín-Acero
Rafael Martín-Acero
JCJavier Cudeiro
Javier Cudeiro

1 September 2010 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
Jesús DevesaJesús Devesa
Jesús Devesa
NCNerea Casteleiro
Nerea Casteleiro
CRCristina Rodicio
Cristina Rodicio
NLNatalia López
Natalia López
PRPedro Reimunde
Pedro Reimunde
Cerebral palsy (CP) is a catastrophic acquired disease, occurring during development of the fetal or infant brain. It mainly affects the motor control centres of the developing brain, but can also affect cognitive functions, and is usually accompanied by a cohort of symptoms including lack of communication, epilepsy, and alterations in behavior. Most children with cerebral palsy exhibit a short stature, progressively declining from birth to puberty. We tested here whether this lack of normal growth might be due to an impaired or deficient growth hormone (GH) secretion. Our study sample comprised 46 CP children, of which 28 were male and 18 were female, aged between 3 and 11. Data obtained show that 70% of these children lack normal GH secretion. We conclude that GH replacement therapy should be implemented early for CP children, not only to allow them to achieve a normal height, but also because of the known neurotrophic effects of the hormone, perhaps allowing for the correction of some of the common disabilities experienced by CP children. Keywords: growth hormone, IGF-I, cerebral palsy, short stature